Current Multimodality Treatments Against Brain Metastases from Renal Cell Carcinoma.
brain metastasis
immune checkpoint inhibitor (ICI), whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), prognosis
renal cell carcinoma
review
targeted therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
06 Oct 2020
06 Oct 2020
Historique:
received:
16
09
2020
revised:
02
10
2020
accepted:
03
10
2020
entrez:
10
10
2020
pubmed:
11
10
2020
medline:
11
10
2020
Statut:
epublish
Résumé
In patients with renal cell carcinoma, brain metastasis is generally one of the poor prognostic factors. However, the recent introduction of molecular target therapy and immune checkpoint inhibitor has remarkably advanced the systemic treatment of metastatic renal cell carcinoma and prolonged the patients' survival. The pivotal clinical trials of those agents usually excluded patients with brain metastasis. The incidence of brain metastasis has been increasing in the actual clinical setting because of longer control of extra-cranial disease. Brain metastasis subgroup data from the prospective and retrospective series have been gradually accumulated about the risk classification of brain metastasis and the efficacy and safety of those new agents for brain metastasis. While the local treatment against brain metastasis includes neurosurgery, stereotactic radiosurgery, and conventional whole brain radiation therapy, the technology of stereotactic radiosurgery has been especially advanced, and the combination with systemic therapy such as molecular target therapy and immune checkpoint inhibitor is considered promising. This review summarizes recent progression of multimodality treatment of brain metastasis of renal cell carcinoma from literature data and explores the future direction of the treatment.
Identifiants
pubmed: 33036276
pii: cancers12102875
doi: 10.3390/cancers12102875
pmc: PMC7600559
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Radiographics. 2018 Nov-Dec;38(7):2021-2033
pubmed: 30339517
In Vivo. 2017 Jul-Aug;31(4):769-771
pubmed: 28652455
Ann Oncol. 2016 Sep;27(suppl 5):v58-v68
pubmed: 27664262
Neurosurgery. 2005 May;56(5):936-45; discussion 936-45
pubmed: 15854241
Cancer. 2011 Dec 15;117(24):5548-59
pubmed: 21647871
Urology. 1990 Oct;36(4):300-2
pubmed: 2219605
J Natl Compr Canc Netw. 2014 Nov;12(11):1517-23
pubmed: 25361798
Cancer. 2011 Nov 1;117(21):4958-65
pubmed: 21484781
N Engl J Med. 2015 Nov 5;373(19):1814-23
pubmed: 26406150
Cancer Res. 2004 Aug 1;64(15):5398-406
pubmed: 15289348
BJU Int. 1999 Sep;84(4):405-11
pubmed: 10468753
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Am J Clin Oncol. 2017 Oct;40(5):439-443
pubmed: 25730604
Semin Radiat Oncol. 2017 Jul;27(3):289-298
pubmed: 28577836
Cancer Med. 2013 Dec;2(6):899-906
pubmed: 24403263
Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):253-8
pubmed: 14697446
Radiat Oncol. 2011 May 15;6:48
pubmed: 21575163
Neurosurgery. 2009 Feb;64(2 Suppl):A26-32
pubmed: 19165071
J Clin Invest. 2013 Jul;123(7):2756-63
pubmed: 23863633
Melanoma Res. 2013 Jun;23(3):191-5
pubmed: 23462208
Clin Genitourin Cancer. 2014 Feb;12(1):50-4
pubmed: 24268852
Anticancer Res. 2019 Jun;39(6):2993-3002
pubmed: 31177140
Ann Oncol. 2012 Apr;23(4):973-80
pubmed: 21890909
PLoS One. 2010 Jun 21;5(6):e11222
pubmed: 20574535
Eur Urol Focus. 2019 May;5(3):474-481
pubmed: 29311016
J Clin Oncol. 2019 Aug 10;37(23):2008-2016
pubmed: 31194611
Int J Clin Oncol. 2019 Oct;24(10):1231-1237
pubmed: 31134469
J Neurosurg. 2012 May;116(5):978-83
pubmed: 22385005
Lancet Oncol. 2009 Aug;10(8):757-63
pubmed: 19615940
J Neurosurg. 2003 Feb;98(2):342-9
pubmed: 12593621
Clin Genitourin Cancer. 2019 Dec;17(6):e1163-e1170
pubmed: 31519468
Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51
pubmed: 9128946
Cancer. 2002 May 15;94(10):2698-705
pubmed: 12173339
Bull Cancer. 2012 Dec;99(12):100-6
pubmed: 23220100
N Engl J Med. 1996 Sep 19;335(12):865-75
pubmed: 8778606
Lancet. 2019 Jun 15;393(10189):2404-2415
pubmed: 31079938
Clin Genitourin Cancer. 2015 Apr;13(2):156-64.e1
pubmed: 25444666
Am J Clin Oncol. 2013 Jun;36(3):258-60
pubmed: 22441343
J Clin Oncol. 2009 Dec 1;27(34):5794-9
pubmed: 19826129
Am J Clin Oncol. 2017 Oct;40(5):444-450
pubmed: 26017484
Cancer. 2016 Oct;122(19):3051-8
pubmed: 27285122
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Case Rep Oncol Med. 2015;2015:629046
pubmed: 26798533
Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):187-93
pubmed: 17881139
Int J Mol Sci. 2014 Jul 03;15(7):11832-46
pubmed: 24995696
J Urol. 2015 Jan;193(1):41-7
pubmed: 25046616
Cancer Genet. 2014 May;207(5):206-13
pubmed: 25027636
J Clin Oncol. 2013 Mar 1;31(7):e114-7
pubmed: 23319695
Front Oncol. 2014 Nov 28;4:325
pubmed: 25506582
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Eur Urol. 2016 Jul;70(1):93-105
pubmed: 26935559
Neurochem Res. 2017 Feb;42(2):625-633
pubmed: 27885577
J Clin Oncol. 2020 Apr 1;38(10):1019-1029
pubmed: 32058845
Clin Genitourin Cancer. 2013 Sep;11(3):311-5
pubmed: 23684422
J Natl Cancer Inst. 2013 Feb 20;105(4):256-65
pubmed: 23291374
Cancer. 2010 Sep 15;116(18):4256-65
pubmed: 20549832
World J Urol. 2018 Nov;36(11):1703-1709
pubmed: 29549485
Lancet Oncol. 2014 Jun;15(7):e248
pubmed: 24872104
J Neurooncol. 2017 Jun;133(2):357-368
pubmed: 28434110
Clin Cancer Res. 2009 Sep 1;15(17):5379-88
pubmed: 19706802
Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):218-24
pubmed: 15337559
J Clin Oncol. 2005 Feb 1;23(4):832-41
pubmed: 15681528
Ann Oncol. 2014 Jan;25(1):149-54
pubmed: 24356626
BJU Int. 2011 Sep;108(5):673-8
pubmed: 21156017
Am J Clin Oncol. 2013 Dec;36(6):620-4
pubmed: 22892430
Eur Urol. 2019 May;75(5):799-810
pubmed: 30803729
World Neurosurg. 2017 Dec;108:151-156
pubmed: 28754641
Urol Oncol. 2012 May-Jun;30(3):290-3
pubmed: 20813555
J Clin Oncol. 2004 Apr 1;22(7):1293-300
pubmed: 15051777
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Cancer. 2008 Oct 1;113(7):1641-8
pubmed: 18671240
Mol Biol Cell. 1999 Aug;10(8):2493-506
pubmed: 10436007
Eur J Cancer. 2012 Feb;48(3):324-32
pubmed: 21803569
J Oncol. 2015;2015:636918
pubmed: 26681942
Ann Oncol. 2010 May;21(5):1027-31
pubmed: 19850637
J Clin Oncol. 2011 May 20;29(15):2027-31
pubmed: 21502558
J Clin Oncol. 2004 Jul 15;22(14):2865-72
pubmed: 15254054
Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1155-61
pubmed: 10725626
N Engl J Med. 2007 May 31;356(22):2271-81
pubmed: 17538086
Lancet Oncol. 2013 Feb;14(2):141-8
pubmed: 23312463
Clin Genitourin Cancer. 2016 Aug;14(4):e401-4
pubmed: 26873436
Biomed Res Int. 2020 Mar 9;2020:6836234
pubmed: 32219138
Int Urol Nephrol. 2019 Jun;51(6):941-949
pubmed: 30953259
J Neurosurg. 2006 Jun;104(6):907-12
pubmed: 16776334
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Neurochirurgie. 2014 Feb-Apr;60(1-2):12-6
pubmed: 24636403
Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):711-7
pubmed: 8040016
Clin Genitourin Cancer. 2015 Feb;13(1):59-66
pubmed: 25023939
JAMA Oncol. 2018 Aug 1;4(8):1123-1124
pubmed: 29327059
J Neurosurg. 2012 Aug;117(2):227-33
pubmed: 22702482
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):916-925
pubmed: 29485071
Anticancer Res. 2015 Jan;35(1):333-6
pubmed: 25550568
Br J Neurosurg. 2009 Apr;23(2):170-8
pubmed: 19306173
Anticancer Drugs. 2016 Jun;27(5):427-32
pubmed: 27045782
J Neurooncol. 1995;23(3):253-6
pubmed: 7673989
Clin Cancer Res. 2009 Oct 1;15(19):6062-9
pubmed: 19773380